Nuveen Asset Management LLC Sells 105,693 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Nuveen Asset Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% during the 4th quarter, Holdings Channel reports. The fund owned 1,133,685 shares of the medical research company’s stock after selling 105,693 shares during the period. Nuveen Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $589,777,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Minot DeBlois Advisors LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $46,000. Mmbg Investment Advisors CO. lifted its holdings in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Mmbg Investment Advisors CO. now owns 14,501 shares of the medical research company’s stock valued at $7,544,000 after acquiring an additional 185 shares during the last quarter. LRI Investments LLC grew its position in Thermo Fisher Scientific by 19.8% in the fourth quarter. LRI Investments LLC now owns 520 shares of the medical research company’s stock worth $270,000 after acquiring an additional 86 shares in the last quarter. Lionshead Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $446,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Thermo Fisher Scientific by 9.7% in the 4th quarter. Janus Henderson Group PLC now owns 1,046,871 shares of the medical research company’s stock valued at $544,615,000 after purchasing an additional 92,668 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Scotiabank decreased their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a report on Friday, April 25th. StockNews.com lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Morgan Stanley increased their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Finally, Evercore ISI reduced their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $428.88 on Wednesday. The company has a 50 day simple moving average of $460.85 and a two-hundred day simple moving average of $513.11. The stock has a market cap of $161.90 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $401.75 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.11 earnings per share. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.